Home
Live Updates
Risankizumab Treatment Demonstrates Superior Efficacy in PsA Over 24 Weeks : comparemela.com
Risankizumab Treatment Demonstrates Superior Efficacy in PsA Over 24 Weeks
At week 24, patients with moderate to severe PsA receiving risankizumab had a significantly higher ACR20 response rate when compared with placebo.
Related Keywords
China ,
Shanxi ,
Fujian ,
Chinese ,
,
Department Of Rheumatology ,
Health Assessment Questionnaire Disability Index ,
Second Hospital Of Shanxi Medical University ,
Psoriasis Area ,
Severity Index ,
Second Hospital ,
Shanxi Medical University ,
American College ,
comparemela.com © 2020. All Rights Reserved.